An Open-Label, Phase 2a Study to Evaluate the Pharmacodynamics of Different Dosing Regimens of TAK-448, a Kisspeptin Agonist, in Male Overweight/Obese Participants With Hypogonadotropic Hypogonadism

Trial Profile

An Open-Label, Phase 2a Study to Evaluate the Pharmacodynamics of Different Dosing Regimens of TAK-448, a Kisspeptin Agonist, in Male Overweight/Obese Participants With Hypogonadotropic Hypogonadism

Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs TAK 448 (Primary)
  • Indications Hypogonadism
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Takeda
  • Most Recent Events

    • 13 Feb 2017 Status changed to discontinued because the study did not achieve the primary efficacy objective.
    • 16 Sep 2016 Results presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes
    • 10 Nov 2015 Obese Type 2 Diabetes Mellitus Subjects With Hypogonadotropic Hypogonadism are excluded from this trial as per ClinicalTrials.gov record. Accordingly changes in title, inclusion-exclusion criteria and purpose .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top